NEW YORK (GenomeWeb) – Biopharmaceutical firm Galmed Pharmaceuticals today announced deals with metabolomics-based assay firm One Way Liver Genomics to develop a companion diagnostic test for Galmed's therapeutic Aramchol for treating non-alcoholic steatohepatitis (NASH). 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.